Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan MIST and Bioavailability Study in Healthy Adults
NCT04991571Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zibotentan in chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Metabolites in Safety Testing sampling at Day 6, Area under plasma concentration time curve from zero to infinity and 3 more. Started Jul 2021; status: completed.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04991571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991571.